{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T22:28:05Z","timestamp":1770589685789,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","award":["K\/ZDS\/007717"],"award-info":[{"award-number":["K\/ZDS\/007717"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vph.2019.106567","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T11:25:35Z","timestamp":1559301935000},"page":"106567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study"],"prefix":"10.1016","volume":"120","author":[{"given":"Konrad","family":"Stepien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karol","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"Zalewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Pac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2019.106567_bb0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA."},{"key":"10.1016\/j.vph.2019.106567_bb0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: burden, mechanisms and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2019.106567_bb0015","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1160\/TH13-02-0131","article-title":"High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients","volume":"110","author":"Lecumberri","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2019.106567_bb0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2006.01804.x","article-title":"Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study","volume":"4","author":"Blom","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2019.106567_bb0025","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.vph.2019.106567_bb0030","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2019.106567_bb0035","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.lungcan.2014.10.003","article-title":"Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer","volume":"86","author":"Kourelis","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.vph.2019.106567_bb0040","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.vph.2019.106567_bb0045","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjh.13556","article-title":"Guideline on aspects of cancer-related venous thrombosis","volume":"170","author":"Watson","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.vph.2019.106567_bb0050","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2019.106567_bb0055","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest."},{"key":"10.1016\/j.vph.2019.106567_bb0060","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","article-title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"17","author":"Farge","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.vph.2019.106567_bb0065","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/jth.13659","article-title":"Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant","volume":"15","author":"Elalamy","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2019.106567_bb0070","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2019.106567_bb0075","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.vph.2019.106567_bb0080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2019.106567_bb0085","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.vph.2019.106567_bb0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"Li","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2019.106567_bb0095","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ajh.25059","article-title":"Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer","volume":"93","author":"Streiff","year":"2018","journal-title":"Am. J. Haematol."},{"key":"10.1016\/j.vph.2019.106567_bb0100","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(95)92535-X","article-title":"Accuracy of clinical assessment of deep-vein thrombosis","volume":"345","author":"Wells","year":"1995","journal-title":"Lancet."},{"key":"10.1016\/j.vph.2019.106567_bb0105","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.vph.2019.106567_bb0110","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2019.106567_bb0115","doi-asserted-by":"crossref","first-page":"379","DOI":"10.20452\/pamw.4287","article-title":"How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues","volume":"128","author":"Tripodi","year":"2018","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.vph.2019.106567_bb0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.07.013","article-title":"Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?","volume":"145","author":"Khorana","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2019.106567_bb0125","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.5603\/KP.2018.0184","article-title":"Similar prevalence of platelet factor 4\/heparin immunoglobulin G antibodies in patients following cardiac surgery and other patients suspected of heparin-induced thrombocytopaenia","volume":"76","author":"Bryk","year":"2018","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.vph.2019.106567_bb0130","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1634\/theoncologist.2017-0473","article-title":"Use of direct oral anticoagulants in patients with cancer: practical considerations for the management of patients with nausea and vomiting","volume":"23","author":"Riess","year":"2018","journal-title":"Oncologist."},{"key":"10.1016\/j.vph.2019.106567_bb0135","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/1076029616677800","article-title":"Oral rivaroxaban for the treatment of symptomatic venous thromboembolism in 400 patients with active cancer: a single-center experience","volume":"23","author":"Pignataro","year":"2017","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.vph.2019.106567_bb0140","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11239-016-1429-1","article-title":"Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study","volume":"43","author":"Mantha","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.vph.2019.106567_bb0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1078155217690922","article-title":"Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin","volume":"24","author":"Nicklaus","year":"2018","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.vph.2019.106567_bb0150","doi-asserted-by":"crossref","first-page":"491","DOI":"10.6004\/jnccn.2018.7008","article-title":"Effectiveness and safety of rivaroxaban in patients with cancer-associated venous thrombosis","volume":"16","author":"Kohn","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.vph.2019.106567_bb0155","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/ejh.13074","article-title":"Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism","volume":"101","author":"Simmons","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.vph.2019.106567_bb0160","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/jth.13153","article-title":"Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial","volume":"13","author":"Agnelli","year":"2015","journal-title":"J. Thromb. Haemost."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189118304324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189118304324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:18:09Z","timestamp":1761527889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189118304324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":32,"alternative-id":["S1537189118304324"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2019.106567","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2019.106567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106567"}}